Medicare Launches GLP-1 Obesity Drug Coverage for Seniors at $50 Monthly

For the first time, Medicare is covering weight-loss drugs, offering eligible beneficiaries GLP-1 medications like Wegovy and Zepbound for $50 per month under a temporary pilot program that began July 1, 2026. The Medicare GLP-1 Bridge program, which runs through December 2027, sidesteps a longstanding federal ban on obesity-only coverage Source: AP News.

What the Program Offers

• Covered drugs include Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo Source: CNN.
• Eligibility requires Medicare Part D enrollment and a BMI of 35 or higher, or a BMI of 27 with conditions like prediabetes or a past heart attack Source: CNBC.
• The $50 copay applies regardless of dosage and is significantly below typical out-of-pocket costs Source: The Guardian.

Rollout and Awareness Challenges

While CMS Administrator Dr. Mehmet Oz called the program a breakthrough, awareness remains low. An Obesity Care Advocacy Network survey found 82% of older Americans were unaware of the new coverage Source: CNBC. Providers worry about administrative burdens, with Dr. Annie Moore from CU Health estimating it could take three to four months for patients to actually receive the drugs Source: The Guardian. Walmart and CVS have stepped in to educate patients and support pharmacy navigation Source: CNBC.